10's of Billions in Market $CELZ is going after with an

New Post Public Reply Private Reply Replies (0) Message Board
Mauibound
817
10's of Billions in Market $CELZ is going after with an alreay commercially stage treatment working now helping ED patients. 
Proven and a Procedure that has just recently hit the market!!! 
The will be hitting the world stave next month to announce their procedure is available world wide now. 

The potential of this stock $CELZ is dizzying!!! 

Our cutting edge technology in autologous stem cell treatment for erectile dysfunction is anticipated to be received by the urologic community with great enthusiasm as our CaverStem TM procedure represents an all-natural alternative for those patients resistant to the use of PDE5 inhibitors such as Viagra and Cialis," said Thomas Ichim PhD, Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc. 

According to multiple publications, approximately 30% of the 30,000,000 men suffering from erectile dysfunction are resistant to such PDE5 inhibitors. 

"Since beginning commercialization of our patented and tested CaverStemTM procedure in November 2017, we have received positive responses from the urology community in the limited cities marketed. We anticipate the introduction of our technology to the attendees of the largest annual urology conference, to promote nationwide interest in CaverStemTM," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
https://www.prnewswire.com/news-releases/crea...19311.html

Creative Medical Technology Holdings to Expand into 10 Billion Dollar per Year Lower Back Pain Market with Acquisition of Issued US Stem Cell Patent 

Clinical Stage Stem Cell Company Continues Aggressive Pursuit of Personalized, Rapid to Implement, Autologous Regenerative Medicine Procedures 

Creative Medical Technology Holdings, Inc.  
May 18, 2017, 12:00 ET 

PHOENIX, May 18, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today the acquisition of issued US patent #9,598,673 covering use of various stem cells for treatment of lower back pain through healing of perfusion defects.  

The Company believes, based on various scientific studies, that a large number of patients with lower back pain undergo progression to disc degeneration due to suboptimal levels of oxygen and nutrients entering the disc. This is believed to be a process similar to what happens in the heart, when the arteries feeding the heart thicken, resulting in reduced heart function. Thickening of arteries feeding the disc is believed to result in starving the disc of nutrients and oxygen, resulting in eventual deterioration and pain. Through administration of stem cells in proximity to the disc, the process is designed to stimulate production of new blood vessels, which will assist the disc to regenerate. 

"Creative Medical Technology Holdings will develop this patent through the same process that we are using for our clinical-stage Caverstem procedure for erectile dysfunction," stated Timothy  Warbington, President and Chief Executive Officer of the Company. "We plan to identify and engage key opinion leaders who will lead clinical trials, which will serve as the basis for accelerated commercialization." 

The Company is currently running a clinical trial using autologous non-manipulated bone marrow stem cells for patients suffering from erectile dysfunction that are non-responsive to standard approaches such as Viagra. Once the trial is completed, the results will serve as the basis for marketing of disposables utilized in administration of stem cells. 

"Although numerous companies are injecting stem cells directly into the disc, direct injection may only cause temporary benefit because the root cause of the pathology, in our opinion, is the reduced blood supply," stated Dr. Amit Patel, Director of Thoracic Surgery at University of Miami and co-founder of Creative Medical Technology Holdings. "By recreating in the microenvironment of the lower back the same thing that we do in atherosclerotic heart patients, we believe we have a novel way to treat this terrible condition that wreaks havoc on our health care system." 

Several studies have shown that administration of stem cells possesses a therapeutic effect in cardiac conditions associated with poor circulation by stimulation of new blood vessel production, a process termed "angiogenesis". The current patent covers stimulation of angiogenesis in the lower back using mesenchymal stem cells. These cells can be used from the same patient, which is considered an "autologous therapy" as well as using stem cells in a universal donor manner, which is termed "allogeneic". 

"The acquisition of this patent not only positions the company to expand into the disc degenerative space, but also provides a powerful platform for collaboration with other companies that are administering regenerative cells directly into the nucleus pulposus of the disc," commented Thomas Ichim, Ph.D., Chief Scientific Officer of the Company and inventor of the technology. "Stem cells are like seeds, they need to be planted into fertile soil.  We feel that in certain patients it is essential to treat the lumbar ischemia, which is present in some patients suffering from disc degenerative disease, which will then allow the stem cells administered directly in the disc to perform their regenerative effects."
https://www.prnewswire.com/news-releases/crea...59902.html

Creative Medical Technology Holdings Announces Superior Immune Modulatory Of AmnioStem Stem Cells Compared To Other Stem Cell Types 

New Data Opens Door to Addressing Multi-Billion Dollar Autoimmune Market 

PR Newswire 
PHOENIX, April 4, 2018 

PHOENIX, April 4, 2018 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB: CELZ) announced today new data demonstrating superior immune modulatory ability of its AmnioStem™ stem cell product when compared head-to-head with bone marrow, adipose tissue, and placental tissue mesenchymal stem cells. The data, which was generated by the Company at its BioLabs research facility in San Diego, showed that AmnioStem™ cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells. 

"Control of molecules such as TNF-alpha represents a multi-billion dollar market. Currently drugs like Humira, Remicade, and Embrel, which are antibodies blocking the TNF-alpha pathway, have sales of over $30 billion per year," said Thomas Ichim, Ph.D, Cofounder and Chief Scientific Officer of Creative Medical Technology Holdings. "Using cells as drugs represents a more viable alternative to existing approaches because the stem cells not only reduce inflammation, but also have ability to induce healing of injured tissue." 

OTCPK:CELZ 30-Year Financial DataThe intrinsic value of OTCPK:CELZPeter Lynch Chart of OTCPK:CELZ 

Dr. Ichim has taken several cell therapies to FDA clearance and clinical trials. The Company is currently preparing an Investigational New Drug (IND) application with the FDA for use of its AmnioStem™ stem cell product for treatment of radiation toxicity through its neurology focused subsidiary CerebroStem LLC and its Medical Director, Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-Oncology, Providence Saint John's Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute. 

"We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market. In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem™ technology include Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, and Lupus," said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. "I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type." 

The AmnioStem™ stem cell is covered by an issued US Patent that was exclusively licensed from the University of California by the Company in 2016.
https://www.gurufocus.com/news/660863/creativ...cell-types

Aloha

Creative Medical Technology Holdings Inc (CELZ) Stock Research Links

CELZ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 0

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 11

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 61

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 18

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 0

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
BBW Lawsuit Puts Guidance and Walmart Claims Under Lens

Updated Category News Views 65

A three-month slice of 2026 has landed Build-A-Bear in the sort of mess investors hate most: a securities complaint centered on whether management's upbeat messaging had already outrun the facts. The lawsuit targets purchases of BBW shares from May 28, 2026 through August 26, 2026, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 66

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 49

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading

Top 5 Most Recently Viewed Articles

Context Labs Launches Innovative Open-Source Emissions Project

Updated Category News Views 204

Context Labs Introduces a Revolutionary Open Decarbonization Project Context Labs is set to make a significant impact in the world of emissions measurement with the launch of its Open Decarbonization Project (ODP). This initiative, in collaboration with key industry players, aims to foster transparency and reliability in carbon and methane emissions reporting using...

Continue Reading
BioAge Labs Exciting Participation in Key Investor Conferences

Updated Category News Views 124

BioAge Labs' Upcoming Investor Conferences BioAge Labs, Inc. (NASDAQ: BIOA), a dynamic player in the biotechnology sector, is ready to take significant strides in the world of investment discussions. This clinical-stage firm specializes in developing therapeutic products targeting metabolic diseases, particularly by exploring the biology of human aging. Engagements at...

Continue Reading
Tiba Biotech’s Revolutionary Vaccine Against Foot-and-Mouth Disease

Updated Category News Views 322

Introduction to Tiba Biotech's Innovative Vaccine Tiba Biotech is at the forefront of changing the landscape of animal health with its novel vaccine specifically designed to combat Foot and Mouth Disease (FMD). This innovative solution has emerged from an extensive challenge study evaluating its effectiveness in cattle, demonstrating that all vaccinated subjects...

Continue Reading
Santhera Pharmaceuticals Secures NICE Clearance for AGAMREE

Updated Category News Views 144

Santhera's Exciting New Journey with AGAMREE® Santhera Pharmaceuticals is making significant strides in the pharmaceutical industry with its innovative medication AGAMREE® (vamorolone), aimed at providing new hope for those affected by Duchenne muscular dystrophy (DMD). With the recent positive guidance from the National Institute for Health and Care Excellence (NICE),...

Continue Reading
Truelink Capital Invests in Horwitz MEP Expansion

Updated Category News Views 57

Truelink Forges New Path with Horwitz Partnership Private equity news always has a way of stirring the pot, and Truelink Capital's latest move is no exception. They announced a significant investment in Horwitz, a Minneapolis-based firm that's been dealing with mechanical, electrical, and plumbing (MEP) services for what seems like a century. Now, they’re digging in...

Continue Reading